Rheumatoid arthritis : remission without biotherapy? The experience of Burkina Faso (West Africa)
Copyright: Aboubakar Ouédraogo et al..
Introduction: the objective of this study was to evaluate the therapeutic response of patients treated with disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis (RA).
Methods: descriptive and analytical single-center cross-sectional study conducted in Burkina Faso from January 2019 to December 2021 in patients with RA meeting American Rheumatism Association/European League against rheumatism criteria. Therapeutic response was assessed according to the criteria of the European League Against Rheumatism, the clinical disease activity index and the simplified disease activity Index after at least six months of treatment.
Results: one hundred and three patients, including 85 women were included. The average age of the patients was 50.14 years ± 15.04 years. Eighty-seven patients (84.47%) were ACPA positive and 50 patients (48.54%) had radiological damage at inclusion. The mean DAS28-CRP, CDAI and SDAI were 5.17, respectively; 32.16 and 35.48 at inclusion compared to 2.53; 7.83 and 8.76 after at least six months of treatment (p<0.0001). Ninety-six patients (93.20%) were treated with methotrexate. According to the criteria of the European League Against Rheumatism, 89 patients (86.41%) were good responders, 62 patients (60.19%) were in remission. Major improvement was observed in 53 patients (51.46%) as assessed by the Clinical Disease Activity Index and the Simplified Disease Activity Index.
Conclusion: despite the unavailability of biotherapies in sub-Saharan Africa, remission of RA can be obtained by optimizing treatment with DMARDs and "tight control".
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
The Pan African medical journal - 47(2024) vom: 08., Seite 12 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Polyarthrite rhumatoïde: la rémission sans biothérapie? L’expérience du Burkina Faso (Afrique de l’Ouest) |
|---|
| Beteiligte Personen: |
Ouédraogo, Aboubakar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antirheumatic Agents |
|---|
| Anmerkungen: |
Date Completed 26.03.2024 Date Revised 26.03.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.11604/pamj.2024.47.12.37537 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370136799 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370136799 | ||
| 003 | DE-627 | ||
| 005 | 20240327000136.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240325s2024 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.11604/pamj.2024.47.12.37537 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1349.xml |
| 035 | |a (DE-627)NLM370136799 | ||
| 035 | |a (NLM)38524108 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Ouédraogo, Aboubakar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rheumatoid arthritis |b remission without biotherapy? The experience of Burkina Faso (West Africa) |
| 246 | 3 | 3 | |a Polyarthrite rhumatoïde: la rémission sans biothérapie? L’expérience du Burkina Faso (Afrique de l’Ouest) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright: Aboubakar Ouédraogo et al. | ||
| 520 | |a Introduction: the objective of this study was to evaluate the therapeutic response of patients treated with disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis (RA) | ||
| 520 | |a Methods: descriptive and analytical single-center cross-sectional study conducted in Burkina Faso from January 2019 to December 2021 in patients with RA meeting American Rheumatism Association/European League against rheumatism criteria. Therapeutic response was assessed according to the criteria of the European League Against Rheumatism, the clinical disease activity index and the simplified disease activity Index after at least six months of treatment | ||
| 520 | |a Results: one hundred and three patients, including 85 women were included. The average age of the patients was 50.14 years ± 15.04 years. Eighty-seven patients (84.47%) were ACPA positive and 50 patients (48.54%) had radiological damage at inclusion. The mean DAS28-CRP, CDAI and SDAI were 5.17, respectively; 32.16 and 35.48 at inclusion compared to 2.53; 7.83 and 8.76 after at least six months of treatment (p<0.0001). Ninety-six patients (93.20%) were treated with methotrexate. According to the criteria of the European League Against Rheumatism, 89 patients (86.41%) were good responders, 62 patients (60.19%) were in remission. Major improvement was observed in 53 patients (51.46%) as assessed by the Clinical Disease Activity Index and the Simplified Disease Activity Index | ||
| 520 | |a Conclusion: despite the unavailability of biotherapies in sub-Saharan Africa, remission of RA can be obtained by optimizing treatment with DMARDs and "tight control" | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Burkina Faso | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a disease-modifying antirheumatic drugs | |
| 650 | 4 | |a therapeutic response | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 700 | 1 | |a Kabore, Fulgence |e verfasserin |4 aut | |
| 700 | 1 | |a Zabsonré/Tiendrebéogo, Wendlasida Joëlle Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Nonguierma, Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Savadogo, Binta |e verfasserin |4 aut | |
| 700 | 1 | |a Abassiri, Kantiga Aida Eudoxie |e verfasserin |4 aut | |
| 700 | 1 | |a Zongo, Yamyellé Enselme |e verfasserin |4 aut | |
| 700 | 1 | |a Damade, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Ouédraogo, Dieu-Donné |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Pan African medical journal |d 2008 |g 47(2024) vom: 08., Seite 12 |w (DE-627)NLM20399910X |x 1937-8688 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2024 |g day:08 |g pages:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.11604/pamj.2024.47.12.37537 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2024 |b 08 |h 12 | ||